Laddar populära aktier...
Flowscape ökade rörelseresultatet under det första kvartalet och orderingången stärktes, vilket är l...
Ökat fokus på nya projekt Carlsquare Equity Research ser den nya influensasatsningen som en lovande ...
Redeye comments on Northbaze Q1 2024 report. EBITDA margin was good.
Redeye provides a short comment on Ortoma’s Q1 report this morning.
Kapsaicinproducenten XP Chemistries EU-ansökan till EFSA (European Food Safety Authority) genomgick ...
Positive growth outlook for margin-accretive Water segment.
CEO Daniel Krook emphasised the increased growth focus Improved growth in '24e on price hikes and a ...
Redeye leaves its comments on today's press release from Xbrane confirming the succesful scale up of...
Redeye notes that a new German clinical study has been published, presenting the improvement the Nev...
Redeye resumes its coverage and updates its view on BeammWave after BeammWave concluded its right is...
Organic sales decline of 11% y-o-y EBIT margin of 8.
Redeye retains its positive view of Vertiseit following a directed share issue.
Redeye provides its initial take on Scandion Oncology's Q1 2024 report.
Redeye provides a short research note following Scandinavian ChemoTech's anouncement of its first or...
Redeye comments on the new multi-year agreement that Dignitana has signed with Konica Minolta in Jap...